Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Shilpa Medicare Ltd - 530549 - Outcome of Board Meeting

 Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31' March, 2019' Auditors' Report for the Financial Year ended 31ST March, 2019' Recommend Dividend of 100% (ire. Re l/- per every share of face value of Rel) for financial year 2018-19 subject to approval of members, To foray into the R&D; activities of specific drug processes by roping prominent technocrats through a new subsidiary company incorporated as Sravathi Advance Process Technologies Private Limited. The resignation tendered by Ms. Namrata Bhutada with effect from 27052019.
27-05-2019
Bigul

Annual report for Shilpa Medicare Ltd. for FY-2019
27-05-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Corporate Action-Board to consider Dividend

 We inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Monday, the 27th of May, 2019 to inter alia transact the following items of business: 1. Consider the recommending of declaration of Dividend for Financial Year 2018-19 and recommend the same for the approval of the members.
20-05-2019
Bigul

Company news: Shilpa Medicare

 Shilpa Medicare on Friday said it has received final approval from the US Food and Drug Administration for Docetaxel Injection in the strengths of 20
17-05-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

 SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2019 ,inter alia, to consider and approve 1. Consider and approve the Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March, 2019 in accordance with Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
17-05-2019
Bigul

Shilpa Medicare Ltd - 530549 - Announcement Under Regulation 30 SEBI (LODR) 2015

 This is to inform you that the Company has received U.S Food and Drug Administration final approval for its ANDA, Docetaxel Injection USP, 20 mg/mL, 80 mg/4 mL (20 mg/mL), and 160 mg/8 mL (20 mg/mL) on 16.05.2019. Docetaxel Injection USP, 20 mg/mL, 80 mg/4 mL and 160 mg/8 mL is a generic equivalent of reference listed drug (RLD) TAXOTERE used in the treatment of Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, Head and Neck Cancer as recommended in the label approved by FDA. According to IQVIA MAT Q1 2019 data, the US market for Docetaxel Injection USP is approximately US$ 32.13 Million.
17-05-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI (LODR) Regulations

 This is to inform you that the Company has received U.S Food and Drug Administration final approval for its ANDA, Zoledronic Acid Injection, 4 mg/5 mL on 15.05.2019. Zoledronic Acid Injection, 4 mg/5 mL is a generic equivalent of reference listed drug (RLD) ZOMETA. It is a bisphosphonate indicated for the treatment of Hypercalcemia of malignancy, Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy as recommended in the label approved by FDA. According to IQVIA MAT Q1 2019 data, the US market for Zoledronic Acid Injection, 4 mg/5 mL is approximately US$ 10.8 Million. This is for your information and doing the needful.
16-05-2019
Bigul

Shilpa Medicare Ltd - 530549 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySHILPA MEDICARE LTD. 2CININE790G01031 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 35 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: VACANCY Designation: COMPANY SECRETARY EmailId: cs@vbshilpa.com Name of the Chief Financial Officer: sushil bajaj Designation: chief financial officer EmailId: sushil.b@vbshilpa.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Certificate Under Regulation 40(9) Of SEBI (LODR), 2015 For Half Year Ended 31St March, 2019.

 With reference to the subject cited above, please find attached herewith the certificate under regulation 40(9) of SEBI (LODR) Regulations, 2015, issued by the D.S. Rao, Practicing Company Secretary in P.S. Rao & Associates for half year ended 31st March 2019.
29-04-2019
Bigul

Shilpa Medicare Ltd - 530549 - Announcement Under Regulation 30

 This is to inform you that the Company has received US Food and Drug Administration approval for its ANDA, Busulfan Injection, 60 mg/10 mL on 18.04.2019. Busulfan Injection, 60 mg/lO mL is a generic equivalent of reference listed drug (RLD), Busulfex Injection, 60 mg/10 mL, used in the treatment of patients with chronic myelogenous leukemia as recommended in the label approved by FDA. According to IQVIA MAT Q4 2018 data, the US market for Busulfan Injection,6O mg/1O mL is approximately US$ 32.8 Million.
20-04-2019
Next Page
Close

Let's Open Free Demat Account